What the FDA MAUDE and Recall Record Reveals About Circumcision Device Failures: A Post-Market Evidence Map for Circumcision Procurement and Supplier Screening (2015–2026)

What Does the FDA Surveillance Record Reveal About Circumcision Devices?

Scenario Question: A distributor quality team, hospital procurement committee, or biomedical-engineering department is evaluating circumcision devices — specifically disposable circumcision staplers, self-detaching rings, and reusable metal clamps. What does the U.S. FDA post-market surveillance record (510(k) clearances, device recalls, and MAUDE adverse events) reveal about how these devices fail, why product code QQR holds zero US filings, and how procurement should translate these findings into tender acceptance criteria?

Direct First-Screen Answer: Across five FDA product codes under 21 CFR 884.4530, the MAUDE adverse-event database holds 942 reports all-time (592 in the 2015–2026 window) ⁴. Reusable Gomco and Mogen clamps under product code HFX account for 851 reports (90.3%), including 5 reported deaths, 427 injuries, and 356 device malfunctions. In contrast, the disposable circumcision stapler product code QQR has zero US 510(k) clearances and zero MAUDE reports ². All 31 US-cleared circumcision devices route through traditional clamp codes (HFX: 27, FHG: 2, FHJ: 2), and major ring innovations (ShangRing, PrePex, Circumplast) were classified under HFX rather than QQR.

Furthermore, the 34 FDA recall records split into two distinct categories: device-intrinsic mechanical failures in metal clamps (such as wrong size subassemblies, bell angle mismatches, out-of-spec clamping force, and clamp arm breakage) versus convenience-tray recalls driven by third-party component defects (such as recalled local anesthetic or antiseptic skin prep swabs inside convenience kits) ³.

Crucially, MAUDE data represents passive surveillance, not true clinical incidence or proof of product hazard ⁵. The high report volume for reusable metal clamps reflects their status as the dominant traditional surgical approach in North America, component wear from repeated autoclave sterilization, and cross-manufacturer part interchanging. International buyers evaluating single-use circumcision staplers should treat the empty US record as a market-entry boundary signal, screen incoming shipments against the mechanical failure modes documented in clamp surveillance, and require evidence from WHO prequalification, CE marking, and NMPA registration.

This evidence map connects directly to our established circumcision surgical research series. It provides the post-market safety foundation for our disposable circumcision stapler mechanism and kit acceptance guide, reinforces the audit standards in our circumcision device manufacturer distributor program qualification guide, complements the sizing models in our disposable circumcision device sizing buyer guide, quantifies the safety backdrop for the disposable circumcision stapler adoption shift, and extends the cross-device method established in our sterile medical device recall evidence map and NPWT pump MAUDE failure mode analysis.

How Does the FDA Classify Circumcision Devices, and Who Holds US Clearances?

To evaluate circumcision device suppliers, procurement officers and regulatory managers must first understand how the U.S. FDA structures device classification under 21 CFR Part 884 (Obstetrics and Gynecology Devices). Section 884.4530 establishes the regulatory umbrella for circumcision devices, dividing them into five dedicated product codes:

As detailed in Table 1, product code HFX (Clamp, Circumcision) holds 27 of the 31 total 510(k) clearances (87.1%) ². The remaining four clearances belong to specialized neonatal bells (FHG: 2 clearances) and protective shields (FHJ: 2 clearances).

A key regulatory insight for international distributors is that product code QQR (Circumcision Device With Stapler) has zero 510(k) clearances in the FDA database ². Disposable circular circumcision staplers — which cut and anastomose foreskin tissue in a single automated pass — originated primarily in Asian surgical markets (such as China, where they hold NMPA Class II registrations) and European CE-marked pathways. Because US legal manufacturers have not submitted 510(k) predicate applications under QQR, the code remains empty.

Furthermore, when international device innovators introduced single-use ring devices into the US market, FDA regulatory clearance was sought by claiming substantial equivalence to traditional metal clamp predicates under product code HFX, rather than creating a new stapler code:

• ShangRing (Wuhu Snnda Medical Treatment Apparatus Co., Ltd.): Cleared under 510(k) K121789 (August 2012) and K131373 (June 2013) under product code HFX.
• PrePex (Circ MedTech Ltd.): Cleared under 510(k) K103695 (January 2012) under product code HFX.
• Circumplast (Novadien Healthcare Ltd.): Cleared under 510(k) K151095 (September 2015) under product code HFX.

For procurement committees, this regulatory structure means that an absence of US 510(k) clearances under QQR is not a indicator of technical failure or safety hazard, but rather a reflection of regional market clearance strategy. Procurement evaluation for disposable staplers must therefore focus on NMPA, CE, and WHO prequalification documentation.

What Do 34 Circumcision Device Recalls Reveal About Failure Mechanisms?

While 510(k) filings show intended regulatory classification, medical device recall logs capture real-world manufacturing and quality control failures. An audit of the FDA Medical Device Recalls database reveals 34 recall records involving circumcision devices ³. Analyzing these recalls by root cause demonstrates a fundamental dichotomy in supply chain risk.

Specific enforcement case studies from Table 2 illustrate the primary failure modes documented in traditional metal clamp hardware:

• Aesculap Gomco Excessive Bleeding (2016): Recall of reusable Gomco clamps due to report of severe post-operative hemorrhage caused by insufficient clamping pressure at the tissue crush line.
• Centurion Bell Angle Mismatch (2019): Recall of circumcision clamp assemblies where an incorrect bell bevel angle could allow tissue to slip, creating a risk of unexpected foreskin resection without scalpel guidance.
• Medline CirClamp Assembly Error (2023): Recall of single-use circumcision clamps due to mismatched bell and base subassemblies packaged in the same sterile pouch.
• Surgical Design Clamp Arm Breakage (2011): Mechanical metal fatigue causing clamp stud or arm fracture during tightening under normal surgical torque.
• DeRoyal Out-of-Spec Clamping (2014): Dimension variances in clamp studs preventing full jaw closure and crush hemostasis.

Conversely, recalls under product code OHG (Circumcision Tray) demonstrate kit-level risk: the circumcision clamp itself was non-defective, but the kit manufacturer packaged recalled third-party components (such as BD syringes, Stryker SafeAir smoke evacuation tubing, Huons lidocaine, or BD ChloraPrep applicators) inside the procedure tray. For buyers sourcing pre-assembled circumcision kits, this highlights the necessity of auditing kit packagers for third-party component change control.

What Do 942 MAUDE Reports Reveal About Reusable Clamps vs Disposable Staplers?

The FDA MAUDE database accumulates post-market adverse-event filings submitted by medical device manufacturers, user facilities, and healthcare professionals. Across all five circumcision product codes, MAUDE contains 942 reports all-time (592 in the 2015–2026 surveillance window) ⁴.

As Table 3 demonstrates, traditional metal clamps under code HFX account for 90.3% of all adverse-event filings (851 reports) ⁴. The 5 reported deaths involved severe pediatric complications, hemorrhage, or systemic sepsis in neonatal settings. The 427 injury reports detail severe clinical events including:

• Subtotal or Total Glans Amputation: Associated primarily with unshielded Mogen-style clamps where excess glans tissue was drawn into the clamping slot prior to scalpel transection.
• Severe Hemorrhage: Caused by Gomco clamp nut looseness, plate warping, or inadequate crush duration failing to achieve vascular thrombosis.
• Laceration and Tissue Tear: Occurring when mismatched bell sizes or worn studs caused uneven pressure distribution during clamping.
• Retained Device Parts: Broken clamp screws, plastic bell fragments, or ring remnants requiring surgical retrieval.

A landmark event in clamp safety history occurred on 29 August 2000, when the FDA CDRH issued a formal Public Health Notification titled 'Potential for Injury from Circumcision Clamps' ⁶. The notification alerted clinicians to recurring glans laceration and amputation hazards with Mogen clamps and warned against interchanging Gomco clamp components manufactured by different companies.

The extreme clinical hazard of clamp mismatch is illustrated by a representative MAUDE filing for an Elmed Mogen clamp (MDR FOI ID 10179996, event date 2020-05-22, product code HFX): during routine procedure execution, the clamp jaw closed across glans tissue, resulting in complete surgical amputation of the glans penis and distal urethra ⁴.

“MAUDE data represents passive post-market surveillance. Submission of an MDR does not constitute an admission that the device caused or contributed to the event, nor can MAUDE counts be used to calculate clinical incidence rates or compare safety between device types.”— U.S. FDA MAUDE Database Limitations Statement <sup class="report-cite"><a href="#s5">5</a></sup>

Procurement committees must interpret these MAUDE figures with rigorous methodology ⁵. Reusable metal clamps carry 851 reports not because they are inherently defective, but because millions of clamp procedures have been performed in US hospitals over decades. Reusable clamps suffer from progressive mechanical wear, metal fatigue, and unauthorized component mixing across operating room sets. Disposable circumcision staplers carry zero US reports because the QQR product code has no US clearances or installed base. Buyers should use this data to recognize the inherent failure modes of clamp mechanics and specify stringent quality controls for single-use devices.

How Do Ring and Stapler Devices Compare on Clinical Safety and WHO Prequalification?

To complement passive FDA surveillance, procurement teams evaluating disposable circumcision staplers and rings must examine published clinical meta-analyses and international regulatory prequalification frameworks.

A comprehensive 2024 meta-analysis by Ahmad et al. published in the Journal of Pediatric Surgery evaluated clinical safety outcomes across neonatal circumcision device designs ⁷. The systematic review compared single-use ring devices against traditional metal clamps across thousands of surgical cases:

• Intraoperative Bleeding Reduction: Ring-based devices demonstrated significantly fewer bleeding events compared with Gomco and Mogen clamps ⁷.
• Procedure Time Standardization: Single-pass ring placement shortened total operative time and eliminated scalpel resection steps.
• Overall Safety Profile: Complication rates for infection, edema, and healing delay showed no significant difference between high-quality ring devices and traditional clamps when performed by trained operators.

On the global health stage, the World Health Organization (WHO) Male Circumcision Device Prequalification Program provides an independent regulatory evidence standard ⁸. WHO prequalification evaluates clinical safety, manufacturing QMS, and field usability for voluntary medical male circumcision (VMMC) programs:

• ShangRing WHO Prequalification: Received WHO prequalification approval following extensive clinical trials in Africa and Asia, confirming low adverse-event rates and high practitioner acceptability ⁹.
• PrePex WHO Prequalification: Prequalified by WHO in 2013 as a non-surgical elastic ring device, establishing clinical evidence protocols for sutureless circumcision.

For hospital buyers in Latin America, Southeast Asia, the Middle East, and Europe, WHO prequalification alongside NMPA Class II registration and CE marking provides robust clinical evidence that bridges the gap left by the empty US QQR 510(k) category.

How Should Procurement Teams Convert Surveillance Evidence Into Tender Specifications?

Hospital procurement committees and distributor quality directors should convert the specific failure mechanisms identified in FDA recall and MAUDE surveillance into non-negotiable tender specifications and lot-acceptance criteria.

In addition to Table 4 specifications, procurement committees should require prospective circumcision device vendors to answer five critical quality-assurance audit questions:

1. 100% Staple Formation Verification: “What automated or manual QC sampling plan (AQL standards) is used to verify titanium staple height, leg alignment, and B-form closure force before lot release?”
2. Bell & Anvil Concentricity: “What dimensional tolerance (in millimeters) is maintained between the inner bell shield and the outer circular cutting ring to prevent tissue pinching or incomplete resection?”
3. Post-Market Vigilance System: “How does your quality management system handle customer feedback and field complaint reporting under ISO 13485:2016 Section 8.2, and what is your historical complaint rate per 10,000 units sold?”
4. Sterilization Validation & Residue Limits: “What Ethylene Oxide (EO) sterilization validation method (ISO 11135) is performed, and what are the certified residual EO and ECH levels per device after aeration?”
5. Component Traceability: “Can your ERP and QMS trace a specific raw material batch (titanium wire, medical ABS, silicone ring) to finished lot numbers delivered under this contract within 12 hours?”

Where Do VEMERIX Disposable Circumcision Devices Fit — and Where Does Due Diligence Begin?

Within our surgical consumable portfolio, VEMERIX supplies five dedicated, NMPA-registered circumcision product lines designed for outpatient surgical efficiency, clinical safety, and standardized outcomes:

• Disposable Circumcision Stapler (Lu Mech Reg. 20192020192): Single-use circular stapler performing simultaneous circumferential cutting and titanium staple anastomosis in a single pass. Factory EO-sterilized and NMPA Class II registered, supplied in multiple adult and pediatric size codes.
• Circumcision Anastomat Kit (Lu Mech Reg. 20162020372): Pre-bundled single-use kit containing the circumcision anastomat, protective bell, and surgical consumables for Adult and Pediatric procedures.
• Disposable Sterile Circumcision Device (Lu Mech Reg. 20222021157): One-step sterile circumcision device optimized for high-throughput ambulatory clinics.
• Circumcision Device Ring (Lu Mech Reg. 20172020238, CE-marked): Biodegradable self-detaching circumcision ring in Adult and Children variants.
• Circum-CARE Post-op Protective Pants (Lu Wei Mech Filing 20190014): Hypoallergenic protective garment designed to protect the wound site and hold dressings in place post-op.

Quality engineering due diligence requires honest evaluation of device formats against hospital infrastructure and surgeon preferences:

VEMERIX provides international distributor partners and hospital procurement teams with full technical packs, 100% factory dimensional inspection certificates, CE/NMPA registration dossiers, and packaging validation data. We welcome independent technical auditing of staple line integrity, blade sharpness, and manufacturing quality management systems.

Frequently Asked Questions: Circumcision Device Safety & Procurement

Q1: Are disposable circumcision staplers FDA-cleared in the United States?
No. In the FDA database, product code QQR (Circumcision Device With Stapler) holds zero 510(k) clearances ². Disposable circular circumcision staplers were developed and commercialized primarily in Asia and Europe under NMPA Class II registration and CE mark certification. US legal manufacturers have not submitted 510(k) predicate applications under QQR. International buyers should evaluate stapler suppliers using NMPA, CE, and WHO evidence rather than expecting a US 510(k).

Q2: What are the most common circumcision device adverse events reported to the FDA?
FDA MAUDE data shows 942 total circumcision filings, overwhelmingly concentrated in traditional metal clamps under product code HFX (851 reports, 90.3%) ⁴. The primary reported adverse events are intraoperative and post-operative hemorrhage, laceration or foreskin slip due to worn clamp plates, glans injury/amputation (associated with unshielded Mogen clamps), and broken clamp studs.

Q3: Does a clean US MAUDE record prove a circumcision device is safe?
No. An empty MAUDE record for product code QQR reflects zero US 510(k) clearances and zero US commercial distribution — not an empirical proof of zero clinical risk ⁵. Conversely, high report counts for metal clamps reflect decades of extensive US hospital usage. Procurement teams must evaluate device safety through clinical trial literature (such as Ahmad et al. 2024), WHO prequalification reports, and rigorous factory lot-acceptance testing.

Q4: Are the ShangRing and PrePex FDA-cleared and WHO-prequalified?
Yes. The ShangRing earned FDA 510(k) clearances (K121789, K131373) under product code HFX and holds WHO prequalification for voluntary male circumcision programs ⁸. PrePex earned FDA clearance (K103695) under HFX and WHO prequalification in 2013. Both devices demonstrate how ring innovations were classified under traditional clamp codes while meeting international global health safety standards.